ArticleThe American journal of pathology2003
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.
Article in The American journal of pathology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 70 citations in OpenAlex.
- Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy.Cancers · 2021Review
- Primed atypical ductal hyperplasia-associated fibroblasts promote cell growth and polarity changes of transformed epithelium-like breast cancer MCF-7 cells via miR-200b/c-IKKβ signaling.Cell death & disease · 2018Article
- Tissue inhibitor of matrix metalloproteinase-1 expression in colorectal cancer liver metastases is associated with vascular structures.Molecular carcinogenesis · 2016Article
- Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.Clinical & experimental metastasis · 2015Article
- Article
- Krüppel-Like Factor 4 Inhibits the Transforming Growth Factor-β1-Promoted Epithelial-to-Mesenchymal Transition via Downregulating Plasminogen Activator Inhibitor-1 in Lung Epithelial Cells.Disease markers · 2015Article
- Unmanipulated native fat exposed to high-energy diet, but not autologous grafted fat by itself, may lead to overexpression of Ki67 and PAI-1.SpringerPlus · 2015Article
- Biomechanics of TGFβ-induced epithelial-mesenchymal transition: implications for fibrosis and cancer.Clinical and translational medicine · 2014Review
- Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells.Journal of cellular physiology · 2012Article
- siRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats.Acta pharmacologica Sinica · 2012Article
- SERPINE1 expression discriminates site-specific metastasis in human melanoma.Experimental dermatology · 2012Article
- The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer.British journal of cancer · 2012Article
- Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment.Biochimica et biophysica acta · 2012Review
- 3D/4D functional imaging of tumor-associated proteolysis: impact of microenvironment.Methods in enzymology · 2012Article
- Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis.Cell cycle (Georgetown, Tex.) · 2011Article
- DNA Methylation Profiles of Protease Nexin 1 (SERPINE2) Gene in Human Cell Lines.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2011Article
- Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.International journal of cancer · 2011Article
- PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes.The Journal of investigative dermatology · 2010Article
- Presence of myofibroblasts and expression of matrix metalloproteinase-2 (MMP-2) in ameloblastomas correlate with rupture of the osseous cortical.Pathology oncology research : POR · 2009Article
- PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma.Journal of oncology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor level of plasminogen activator inhibitor-1 (PAI-1) is an informative biochemical marker of a poor prognosis in several cancer types. However, the tumor biological functions of PAI-1 and the identity of PAI-1-expressing cells are controversial. With the aim of immunohistochemically localizing PAI-1 in formalin-fixed, paraffin-embedded invasive ductal breast carcinoma samples, we raised new polyclonal antibodies against PAI-1 from different expression systems. The antibodies were affinity purified by absorption on immobilized preparations of PAI-1 different from those used for immunization. The specificity of the antibodies was ensured by immunoblotting analysis. In immunohistochemistry, the staining pattern obtained with the antibodies showed a good correlation with the PAI-1 mRNA expression pattern. In all 25 cases analyzed, PAI-1 immunoreactivity was predominantly localized in fibroblast-like cells. Double-immunofluorescence analyses showed co-expression of PAI-1 and alpha-smooth muscle actin in these cells, suggesting that they are myofibroblasts. PAI-1 was also seen in some myoepithelial cells surrounding occasional foci of ductal carcinoma in situ (9 of 25), some endothelial cells (8 of 25), some cancer cells (3 of 25), and some mast cells (6 of 25). In conclusion, we have provided a robust immunohistochemical procedure for detection of PAI-1 and shown that the majority of the PAI-1-expressing cells in invasive ductal breast carcinomas are myofibroblasts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.